Zenas’ autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study
Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The…